IP Library › Granted Patent US 11,542,296
Granted Patent B2
US 11,542,296 · App. 17/049,976 · Granted Jan 3, 2023

Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders

Inventor: Doodipala Samba Reddy (Bryan, TX)
Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
C07J43/003A61P25/08C07J5/0015C07J41/0088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,542,296
App. No.
17/049,976
Granted
Jan 3, 2023
Kind
B2
Abstract

Described herein is the chemical structure of neurosteroid derivative compounds, methods of synthesizing the derivatives, and their uses in treating disorders, including those of the central nervous system. These compounds are readily synthesized and have improved pharmaceutical properties, including water solubility, compared to known neurosteroids.

Claims (16)

1. A method for treating epilepsy comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmaceutically acceptable salt of said compound, or a pharmaceutical composition comprising a pharmaceutically acceptable excipient and said compound, said compound or said pharmaceutically acceptable salt being selected from:

2. The method of claim 1 , wherein the compound is administered to a patient by oral, parenteral, intravenous, transdermal, inhalation, intracerebral or topical administration in a suitable formulation.

3. A method for treating epilepsy comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmaceutically acceptable salt of said compound, or a pharmaceutical composition comprising a pharmaceutically acceptable excipient and said compound, said compound or pharmaceutically acceptable salt being selected from:

4. The method of claim 3 , wherein the compound is given to a patient by oral, parenteral, intravenous, transdermal, inhalation, intracerebral or topical administration in a suitable formulation.

5. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

6. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

7. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

8. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

9. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

10. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

11. The method of claim 1 , wherein said compound or said pharmaceutically acceptable salt is

12. The method of claim 3 , wherein said compound or said pharmaceutically acceptable salt is

13. The method of claim 3 , wherein said compound or said pharmaceutically acceptable salt is

14. The method of claim 3 , wherein said compound or said pharmaceutically acceptable salt is

15. The method of claim 3 , wherein said compound or said pharmaceutically acceptable salt is

16. The method of claim 3 , wherein said compound or said pharmaceutically acceptable salt is

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 26, 2023
From: TEXAS A&M UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065365/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2020
From: REDDY, DOODIPALA SAMBA
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 054161/0702 →
Continuity (2)
Provisional Application 62661187 · Apr 23, 2018
Related Publication 20210238220A1 · Aug 5, 2021
Cited By (1)
US 12,509,487